In Phase C, members will get ABBV-744 and oral navitoclax. In Section D, members will obtain ABBV-744 and ruxolitinib. Individuals will get treatment till condition progression or perhaps the individuals are not able to tolerate the study drugs. - "Our study revealed the very important part of the KLF16/MYC regulatory https://yehudau000hsd2.daneblogger.com/profile